People Round-Up: Bhadauria Named As Amneal CSO

Amneal gets a new CSO, Acino restructures its board under a new chair, the AAM adds an assistant general counsel and the British Biosimilars Association names a vice-chair, as well as other people movements from around the generics, biosimilars and value-added medicines industries.

People
• Source: Shutterstock

Amneal Pharmaceuticals Inc. has named former Apotex vice-president of global R&D, Pradeep Bhadauria, as Amneal’s chief scientific officer with immediate effect, succeeding current CSO Shankar Hariharan who will leave the company on 24 May. Citing Bhadauria’s “significant R&D expertise” – with over 20 years of experience leading development for generics and specialty pharmaceutical firms including Actavis – Amneal said he had overseen the development and filing of more than 200 products, “including numerous first-to-file and first-to-market opportunities”. In particular, noted Amneal’s president and CEO, Rob Stewart, Bhadauria had “demonstrated strength in developing complex generics and other difficult-to-formulate products”, which would be “a strong asset to our company as we continue to diversify our pipeline and portfolio”.

Acino has restructured its board into a “smaller, streamlined” form following the appointment of John Beighton as chairman, succeeding...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Leadership

More from Generics Bulletin